Bioidentical estradiol gel for hormone therapy in menopause

References

• Belchetz PE. Hormonal treatment of postmenopausal women. N. Engl. J. Med.330, 1062–1071 (1994).
   PubMed Web of Science ®Google Scholar
• Porter M, Penney GC, Russel D, Russell E, Templeton A. A population based survey of women’s experience of the menopause. Br. J. Obstet. Gynaecol.103, 1025–1028 (1996).
   PubMedGoogle Scholar
• Birge SJ. The use of estrogen in older women. Clin. Geriatr. Med.19, 617–627 (2003).
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17β-estradiol dose for treating vasomotor symptoms. Obstet. Gynecol.95, 726–731 (2000).
   PubMed Web of Science ®Google Scholar
• Jackson RD, Wactawski-Wende J, LaCroix AZ et al.; Women’s Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women’s Health Initiative randomized trial. J. Bone Miner. Res.21(6), 817–828 (2006).
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z et al.; Women’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA290, 1729–1738 (2003).
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA280, 605–613 (1998).
   PubMed Web of Science ®Google Scholar
• Hulley S, Furberg C, Barrett-Connor E et al.; HERS Research Group. HERS II noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA288, 58–66 (2002).
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL et al., and Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA288, 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR et al.; Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA291, 1701–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Hulley SB, Grady D. The WHI estrogen-alone trial: do things look any better? JAMA291, 1769–1771 (2004).
   PubMed Web of Science ®Google Scholar
• Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet362, 419–427 (2003).
   PubMed Web of Science ®Google Scholar
• Ostrzenski A, Ostrzenska KM. WHI clinical trial revisit: imprecise scientific methodology disqualifies the study’s outcomes. Am. J. Obstet. Gynecol.193(5), 1599–1604 (2005).
   PubMedGoogle Scholar
• Mastorakos G, Sakkas EG, Xydakis AM, Creatsas G. Pitfalls of the WHIs: Women’s Health Initiative. Ann. NY Acad. Sci.1092, 331–340 (2006).
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA297(13), 1465–1477 (2007).
   PubMed Web of Science ®Google Scholar
• Klaiber EL, Vogel W, Rako S. A critique of the Women’s Health Initiative hormone therapy study. Fertil. Steril.84, 1589–1601 (2005).
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N. Engl. J. Med.343, 522–529 (2000).
   PubMed Web of Science ®Google Scholar
• Ho JY, Chen MJ, Sheu WH et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum. Reprod.21(10), 2715–2720 (2006).
   PubMed Web of Science ®Google Scholar
• Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause14(3), 373–384 (2007).
   PubMed Web of Science ®Google Scholar
• Notelovitz M. Clinical opinion: the biologic and pharmacologic principles of estrogen therapy for symptomatic menopause. MedGenMed8(1), 85 (2006).
   PubMedGoogle Scholar
• Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA289, 537–538 (2003).
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force 2005. Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions.
   Google Scholar
• American College of Obstetricians and Gynecologists. Women’s Health Care Physicians. Executive summary: hormone therapy. Obstet. Gynecol.104, 1S–4S (2004).
   Google Scholar
• Ettinger B, Ensrud KE, Wallace R et al. Effects of ultralow-dose trans-dermal estradiol on bone mineral density: a randomized clinical trial. Obstet. Gynecol.104, 443–451 (2004).
   PubMed Web of Science ®Google Scholar
• Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol.24, 571 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet. Gynecol.105, 779–787 (2005).
   PubMed Web of Science ®Google Scholar
• Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas57(1), 81–84 (2007).
   PubMed Web of Science ®Google Scholar
• Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol.85, 304–313 (1995).
   PubMed Web of Science ®Google Scholar
• Tanigawara Y. Role of p-glycoprotein in drug disposition. Ther. Drug Monit.22, 137–140 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson JA. Drug target pharmacogenomics: an overview. Am. J. Pharmacogenomics1, 271–281 (2001).
   PubMedGoogle Scholar
• Tempfer CB, Schneeberger C, Huber JC. Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology. Pharmacogenomics5, 57–65 (2004).
   PubMed Web of Science ®Google Scholar
• Hwang CS, Kwak HS, Lim HJ et al. Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J. Steroid Biochem. Mol. Biol.101, 246–253 (2006).
   PubMed Web of Science ®Google Scholar
• Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause11, 356–367 (2004).
   PubMed Web of Science ®Google Scholar
• Walker CR. Bioidentical hormone replacement therapy. A natural option for perimenopause and beyond. Adv. Nurse Pract.9, 39–42 (2001).
   PubMedGoogle Scholar
• Vining RF, McGinley RA. The measurement of hormones in saliva: possibilities and pitfalls. J. Steroid Biochem.27, 81–94 (1987).
   PubMedGoogle Scholar
• Klee GG, Heser DW. Techniques to measure testosterone in the elderly. Mayo Clin. Proc.75, S19–S25 (2000).
   Google Scholar
• Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric7, 347–356 (2004).
   PubMed Web of Science ®Google Scholar
• Fraser JS, Wang Y. New delivery systems for hormone replacement therapy. In: Progress in the Management of the Menopause. Wren BG. Parthenon Publishing, London, UK, 58–67 (1997).
   Google Scholar
• Jarvinen A, Nykanen S, Paasiniemi L. Absorption and bioavailability of estradiol from a gel, a patch and a tablet. Maturitas32, 103–113 (1999).
   PubMed Web of Science ®Google Scholar
• Cushman M, Legault C, Barrett-Connor E et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation100, 717–722 (1999).
   PubMed Web of Science ®Google Scholar
• Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med.331, 417–424 (1994).
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Oger E, Plu-Bureau G. Estrogen and thromboembolism risk study group. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet362, 428–42 (2003).
   PubMed Web of Science ®Google Scholar
• Kawano H, Yasue H, Hirai N et al. Effects of transdermal and oral estrogen supplementation on endothelial function, inflammation and cellular redox state. Int. J. Clin. Pharmacol. Ther.41, 346–353 (2003).
   PubMedGoogle Scholar
• Canonico M, Oger E, Plu-Bureau G et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation115(7), 840–845 (2007).
   PubMed Web of Science ®Google Scholar
• Hope S, Rees MCP. Why do British women start and stop hormone replacement therapy? J. Br. Menopause Soc.1, 26–27 (1995).
   Google Scholar
• Paoletti AM, Pilia I, Nannipieri F, Biagini C, Melis GB. Comparison of pharmacokinetic profiles of 17β-estradiol gel 0.6 mg/g (Gelestra) with transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state. Maturitas40, 203–209 (2001).
   PubMedGoogle Scholar
• Jarvinen A, Granander M, Nykanen S, Laine T, Geurts P, Viitanen A. Steady state pharmacokinetics of oestradiol in postmenopausal women: effects of application area and washing. J. Obstet. Gynecol.104(Suppl.), 14–18 (1997).
   Google Scholar
• Bakken K, Eggen AE, Lund E. Side-effects of hormone replacement therapy and influence on pattern of use among women aged 45–64 years. The Norwegian Women and Cancer (NOWAC) study 1997. Acta Obstet. Gynecol. Scand.83, 850–856 (2004).
   PubMed Web of Science ®Google Scholar
• Lehman L, Simes S. Trough serum levels of estradiol, estrone, and estrone sulfate following transdermal application of Bio-E-Gel™. Fertil. Steril.82, S186–S186 (2004).
   PubMedGoogle Scholar